| FDA: Finasteride or dutasteride may increase risk of high-grade prostate cancer. |
|
| FDA MedWatch: FDA notified healthcare professionals that the Warnings and Precautions section of the labels for the 5-alpha reductase inhibitor (5-ARI) class of drugs has been revised to include new safety information about the increased risk of being diagnosed with a more serious form of prostate cancer (high-grade prostate cancer). |